Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck-Wellcome Trust JV appoints Dr Goel as CSO

This article was originally published in Scrip

Executive Summary

MSD Wellcome Trust Hilleman Laboratories, an R&D joint venture between Merck & Co and the Wellcome Trust, has appointed Dr Akshay Goelchief scientific officer. Dr Goel, who was previously director of new vaccines at Serum Institute of India, has been credited with the development of a meningococcal C conjugate vaccine (NeisVac-C) in the UK and a Haemophilus influenzae type B and meningococcal A conjugate (for sub-Saharan Africa) vaccine in India. The joint venture expects to develop affordable vaccines for low-income countries and its laboratories will be based in India. It will operate on a not-for-profit basis, with Merck and the Wellcome Trust planning to invest equally in the venture with a combined cash contribution of £90 million over the next seven years. It aims to support a staff of about 60 researchers and developers.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC009866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel